文献速递眼底病与葡萄膜炎

厚脉络膜新生血管病变玻璃体腔注射抗血管内皮生长因子后脉络膜厚度变化

Changes in Choroidal Thickness After Intravitreal Injection of Anti-Vascular Endothelial Growth Factor in Pachychoroid Neovasculopathy.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2018-01-01

本研究为观察性回顾性连续病例系列,纳入18例(18眼)因厚脉络膜新生血管病变接受抗血管内皮生长因子(VEGF)治疗的患眼,对侧18眼为对照。12个月随访时患眼黄斑中心凹下脉络膜厚度(SFCT)较基线显著下降,对侧眼无显著变化;最佳矫正视力(BCVA)无显著差异。

要点

  • 患眼SFCT从基线平均317.7±39.9 μm降至12个月266.9±56.3 μm(P≤0.001),下降16%。
  • 12个月SFCT变化与注射次数高度相关(rs=0.762,P≤0.001)。
  • 对侧眼SFCT在12个月内无显著变化(中位数267.5 vs 267.0 μm;P=0.930)。

核心结论

  • 接受抗VEGF注射治疗的厚脉络膜新生血管病变患眼,脉络膜厚度从基线至12个月显著下降。
  • 这种下降可能归因于脉络膜血管通透性降低,进而与厚脉络膜新生血管病变活动性下降相关。
  • 作者认为需要前瞻性研究来证实这些发现。

研究设计与样本

  • 观察性、回顾性、连续病例系列,纳入18例(18眼)因厚脉络膜新生血管病变接受抗VEGF治疗的患者,对侧18眼作为对照。
  • 所有眼均接受扫频源光学相干断层扫描(SS-OCT)和光学相干断层扫描血管成像(OCTA)评估。

主要发现

  • 患者平均年龄68.3±7.0岁,平均随访16.4±2.0个月。
  • 患眼最佳矫正视力(BCVA)从基线至12个月随访无差异(ETDRS评分中位数77.5 vs 76字母,P=0.074;logMAR中位数0.22 vs 0.22,P=0.453)。
  • 患眼黄斑中心凹下脉络膜厚度(SFCT)从基线平均317.7±39.9 μm降至12个月266.9±56.3 μm(P≤0.001);12个月SFCT中位变化44.0 μm(范围17-133 μm),下降16%。
  • 12个月SFCT变化与玻璃体腔注射次数高度相关(rs=0.762,P≤0.001)。
  • 对侧眼SFCT在12个月研究期间无显著变化(中位数267.5 vs 267.0 μm;P=0.930)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需要前瞻性研究来证实这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We evaluate changes in choroidal thickness after intravitreal injection (IVI) therapy for pachychoroid neovasculopathy (PNV). METHODS: An observational, retrospective, consecutive case series was studied of 18 patients (18 eyes) who underwent anti-vascular endothelial growth factor (VEGF) therapy for PNV. The 18 fellow eyes in these patients were used as controls. All eyes were evaluated with swept-source optical coherence tomography (SS-OCT) and optical coherence tomography angiography (OCTA). RESULTS: Mean patient age was 68.3 ± 7.0 years. Mean follow-up was 16.4 ± 2.0 months. No differences in the best-corrected visual acuity (BCVA) of the affected eyes were observed between baseline and 12-month follow-up (median Early Treatment of Diabetic Retinopathy Study [ETDRS] score, 77.5 vs. 76 letters, P = 0.074; median logMAR, 0.22 vs. 0.22, P = 0.453). However, subfoveal choroidal thickness (SFCT) decreased significantly from a mean of 317.7 ± 39.9 μm at baseline to 266.9 ± 56.3 μm at 12 months (P ≤ 0.001). Median change in SFCT at 12 months was 44.0 μm (range, 17-133 μm). SFCT decreased by 16% from baseline to month 12. The change in SFCT at 12 months was highly correlated with the number of IVI (rs = 0.762, P ≤ 0.001). No significant changes in SFCT were observed in the fellow eyes over the 12-month study period (median, 267.5 vs. 267.0 μm; P = 0.930). CONCLUSIONS: Choroidal thickness decreased significantly from baseline to month 12 in eyes with PNV treated with anti-VEGF injections. This reduction might be attributable to a reduction in choroidal vascular permeability and, thus, with a decrease in PNV activity. Prospective studies are needed to confirm these findings.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Padrón-Pérez N, Arias L, Rubio M, et al. Changes in Choroidal Thickness After Intravitreal Injection of Anti-Vascular Endothelial Growth Factor in Pachychoroid Neovasculopathy. Invest Ophthalmol Vis Sci. 2018. PMID: 29490349. doi:10.1167/iovs.17-22144

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。